The prognostic utility of these additional mutations identified in patients with suspected JAK2-negative PV supports the role of NGS-based genetic testing for patients, and may also be helpful in elucidating other myeloid drivers for the rare patients with JAK2-negative PV, a poorly characterized subgroup requiring further research. Here, JAK2 is linked to acquired polycythemia vera.